ABSTRACT & COMMENTARY

Antiplatelet Therapy After TAVR: More ARTE Than Science

July 1, 2017

The current clinical standard of dual antiplatelet therapy following transcatheter aortic valve replacement is controversial.

Issue Date: July 1, 2017

Table of Contents

Late-breaking Clinical Trials from the Heart Rhythm Society May 2017 Scientific Sessions
Antiplatelet Therapy After TAVR: More ARTE Than Science
Distinguishing Ischemic From Non-ischemic Cardiomyopathy Clinically
B-type Natriuretic Peptide Is Less Useful in Elderly Patients With Dyspnea
Left Ventricular Volume Affects Function in Chemotherapy Patients

Financial Disclosure: Clinical Cardiology Alert’s Physician Editor Michael H. Crawford, MD, Peer Reviewer Susan Zhao, MD, Nurse Planner Aurelia Macabasco-O’Connell, PhD, ACNP-BC, RN, PHN, FAHA, Editor Jonathan Springston, Executive Editor Leslie Coplin, and AHC Media Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements